




Antibody-drug-conjugate LC-MS characterization and GMP solutions; supporting ADC drug developments from pre-clinics to commercial


Solvias provides fast turnaround time, high quality LC-MS based antibody-drug conjugates (ADC) analytical solutions, supporting clients from pre-clinical and early clinical phases characterization to late clinical phase and commercial GMP release and stability studies. The comprehensive set of in-house developed platform LC-MS/MSMS methods were successfully applied to many ADC-products and are acknowledged by authorities. We use state-of-the-art LC-MS technology and workflows for reliable and accurate determination of the drug-to-antibody ratio (DAR), site of drug conjugation, drug characterization and protein conformation of your ADCs. Our LC-MS methods can measure the cleaved/released payload, the conjugated antibody, as well as the individual drug load distribution of your ADCs. Structural changes (e.g. comparing the naked antibody and the ADC) and protein-protein interactions can be investigated using our fully automated hydrogen-deuterium-exchange mass spectrometry (HDX-MS) platform. Whether you need ADC analysis for pre-clinical, clinical studies or commercial release, we have the expertise and experience to deliver high-quality results in a timely manner. Contact us under BioMS@solvias.com to find out more about our comprehensive ADC analytical solutions using LC-MS/MSMS.



DAR calculation by HIC-HPLC and LC-MS (intact/reduced)




Conjugation site characterization by LC-MS/MS



Structure analysis by HDX-MS analysis

Customized analysis of target Antibody-drug conjugate (ADC) to answer your questions in:

- ✓ Drug-to-antibody ratio (DAR)
- ✓ Protein conformation
- ✓ Site of drug conjugation
- ✓ Drug characterization



In-detail drug and linker analysis by LC-MS